(1) Department of Medicine, McMaster University, Hamilton, Ontario, Canada; (2) Department of Biochemistry and Biomedical Sciences and Henderson Research Centre, Hamilton,Ontario, Canada

(1) Institute of Cardiology and Center of Excellence on Aging, “G. d’Annunzio” University, Chieti, Italy

(1) Baker Heart Research Institute, Centre for Thrombosis & Myocardial Infarction, Melbourne, Victoria, Australia; (2) Haemostasis, Thrombosis & Vascular Biology Unit, University of Birmingham Centre for Cardiovasculkar Sciences, City Hospital, Birmingham, UK

(1) Lehigh Valley Health Network, Allentown, Pennsylvania, USA; (2) Columbia University, Medicine, New York, New York, USA

(1) Medizinische Klinik III, Kardiologie und Kreislauferkrankungen, Eberhard Karls Universität Tübingen, Tübingen, Germany

(1) Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, Virginia, USA; (2) Institute for Structural Biology and Drug Discovery, Virginia Commonwealth University, Richmond, Virginia, USA; (3) Department of Chemistry, Virginia Commonwealth University, Richmond, Virginia

(1) Centro Cardiologico Monzino, IRCCS, Milano, Italy; (2) Department of Cardiovascular Sciences, Università degli Studi di Milano, Milano, Italy; (3) Department of Pharmacological Sciences, Università degli Studi di Milano, Milano, Italy; (4) Department of Inflammation and Immunology, Istituto Clinico Humanitas, Rozzano, Milano, Italy

(1) Centro de Investigaciones Biológicas, Spanish Research Council (CSIC), Madrid, Spain; (2) Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; (3) Present address: Siemens S.A., Sector Healthcare, Getafe, Spain; (4) Spanish HHT Unit, Hospital de Sierrallana. Torrelavega, Santander, Spain

(1) Duke University School of Medicine, Durham, North Carolina, United States; (2) Sinai Center for Thrombosis Research, Baltimore, Maryland, United States

(1) Division of Cardiovascular Medicine, Department of Medicine, University of Florida, Gainesville, Florida, USA; (2) Division of Cardiovascular Medicine, Department of MolecularGenetics and Microbiology, University of Florida, Gainesville, Florida, USA; (3) Robarts Research Institute, Department of Medicine, University of Western Ontario, London, Ontario, Canada; (4) Department of Microbiology and Immunology, Department of Medicine, University of Western Ontario, London, Ontario, Canada; (5) Viron Therapeutics, Inc., London, Ontario, Canada; (6) Department of Medicine, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK; (7) Division of Cardiology, Department of Medicine, University of Western Ontario, London, Ontario, Canada

(1) Department of Medicine/ Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany; (2) Department of Pharmacology, Center for Cardiovascular Research (CCR),Charité Universitätsmedizin-Berlin, Berlin, Germany; (3) Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria

(1) Department of Cardiology, Medical University of Vienna, Vienna, Austria; (2) Department of Transfusion Medicine, Medical University of Vienna, Vienna, Austria

(1) Institute for Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Kiel, Germany

(1) Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA; (2) Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA; (3) Miller School of Medicine, University of Miami, Miami, Florida, USA; (4) Cardiac Catheterization Laboratory, University of Miami Hospital, Miami, Florida, USA; (5) Regado Biosciences, Inc, Durham, North Carolina, USA; (6) Department of Genetics, Center for Genetics and Cellular Therapies, Duke University Medical Center, Durham, North Carolina, USA

(1) Hemophilia Centre – Internal and Vascular Medicine, Department of Internal Medicine, University of Perugia, Perugia, Italy; (2) U.O. Medicina Generale, Azienda A.S.L. n. 1dell’Umbria – Città di Castello and Umbertide, Italy; (3) Institute of Internal Medicine, Angiology and Arteriosclerosis, Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy; (4) Ospedale di Norcia, Azienda A.S.L. n. 2 dell’Umbria, Perugia, Italy

(1) Department of Cardiology, Lund University Hospital, Sweden; (2) Department of Cardiology, Aalborg Hospital, Aarhus University Hospital, Denmark; (3) Department of InternalMedicine, Asker and Baerum Hospital, Norway; (4) AstraZeneca R&D, Mölndal, Sweden

(1) Politecnico di Milano, Dipartimento di Chimica, Materiali e Ingegneria Chimica “G. Natta”, Milano, Italy; (2) OPOCRIN S.p.A., Corlo di Formigine (Modena), Italy; (3) Departamento de Bioquímica da Universidade Federal do Rio Grande do Norte, Brasil; (4) Istituto di Ricerche Chimiche e Biomediche “G. Ronzoni”, Milano, Italy

(1) Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan; (2) First Research Department, The Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan; (3) Department of General Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan

(1) Endocrinology and Nutrition Service, Department of Internal Medicine (Universitat Autònoma de Barcelona) Germans Trias i Pujol University Hospital, Badalona, Barcelona, Spain; (2) Hemotherapy and Haemostasis Service, IDIBAPS, Hospital Clinic, Barcelona, Spain; (3) Endocrinology Unit, Mataró Hospital, Spain

(1) Deutsches Herzzentrum und 1. Medizinische Klinik der Technischen Universität München, München, Germany